Refocusing Tarveda on tumor-targeted mini-drug conjugates

February 8, 2017 Christoph Graener

In the past 18 months, Tarveda Therapeutics has been refocusing its efforts on Pentarins, its miniaturized drug conjugates, designed to target, penetrate and eradicate solid tumors. Having raised USD 38 million early in 2016 to execute the plan, Tarveda president, CEO and interim chairman, Drew Fromkin, explains to Mike Ward, Informa Pharma Intelligence insights global director of content, what progress has been made and what milestones are on the horizon.

Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Drew Fromkin – President, CEO and Interim Chairman, Tarveda Therapeutics

Previous Article
AmpliPhi advances phage in clinic to address microbial infections

AmpliPhi CEO Scott Salka explains how he is looking to secure sufficient capital to support the Phase II de...

Next Article
Shield pilots ironclad specialty future with Feraccru

Bolstered with a successful launch in Germany and the UK of its anemia treatment Feraccru, Shield Therapeut...